Overview

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma